PT90659A - Process for the manufacture of diol-containing renin inhibitors - Google Patents

Process for the manufacture of diol-containing renin inhibitors

Info

Publication number
PT90659A
PT90659A PT90659A PT9065989A PT90659A PT 90659 A PT90659 A PT 90659A PT 90659 A PT90659 A PT 90659A PT 9065989 A PT9065989 A PT 9065989A PT 90659 A PT90659 A PT 90659A
Authority
PT
Portugal
Prior art keywords
diol
manufacture
renin inhibitors
containing renin
inhibitors
Prior art date
Application number
PT90659A
Other languages
English (en)
Other versions
PT90659B (pt
Inventor
Richard Himmelsbach
William C Patt
John C Hodges
Joseph T Repine
James S Kaltenbroun
Ilma Sircar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PT90659A publication Critical patent/PT90659A/pt
Publication of PT90659B publication Critical patent/PT90659B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT90659A 1988-05-27 1989-05-24 Processo para a preparacao de inibidores de renina contendo diois PT90659B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19999088A 1988-05-27 1988-05-27
US07/321,638 US5036053A (en) 1988-05-27 1989-03-15 Diol-containing renin inhibitors

Publications (2)

Publication Number Publication Date
PT90659A true PT90659A (pt) 1989-11-30
PT90659B PT90659B (pt) 1994-10-31

Family

ID=26895354

Family Applications (1)

Application Number Title Priority Date Filing Date
PT90659A PT90659B (pt) 1988-05-27 1989-05-24 Processo para a preparacao de inibidores de renina contendo diois

Country Status (11)

Country Link
US (1) US5036053A (pt)
EP (1) EP0343654A3 (pt)
JP (1) JPH0267297A (pt)
KR (1) KR900018137A (pt)
AU (1) AU625456B2 (pt)
DK (1) DK258589A (pt)
FI (1) FI892521A (pt)
NO (1) NO892136L (pt)
NZ (1) NZ229281A (pt)
PH (1) PH26816A (pt)
PT (1) PT90659B (pt)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107658T1 (de) * 1988-01-26 1994-07-15 Sankyo Co Renin inhibierende polypeptide, ihre herstellung und anwendung.
US5238923A (en) * 1989-05-26 1993-08-24 Warner-Lambert Company Amino-substituted heterocycles as renin inhibitors
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5227401A (en) * 1991-10-29 1993-07-13 G. D. Searle & Co. Ethynyl alanine amino diol compounds for treatment of hypertension
US5223535A (en) * 1991-10-29 1993-06-29 G. D. Searle & Co. Propargyl glycine amino propargyl diol compounds for treatment of hypertension
EP0539976A1 (en) * 1991-10-29 1993-05-05 G.D. Searle & Co. Ethynyl-alanine-amino-diol compounds for treatment of hypertension
NZ249022A (en) * 1992-02-13 1996-06-25 Warner Lambert Co Preparation of (-)-(s)- and (+)-(r)- ethyl (5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7 -yl) carbamate; pyridyl amino hydroxamic acid precursors
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5373017A (en) * 1992-08-14 1994-12-13 G. D. Searle & Co. Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5252591A (en) 1992-08-14 1993-10-12 G. D. Searle & Company Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension
US5298505A (en) * 1992-08-14 1994-03-29 G. D. Searle & Co. Ethynyl alanine amino diol compounds having a piperazinyl-terminated group or a piperazinyl-alkylamino-terminated group for treatment of hypertension
US6376506B1 (en) 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6493178B1 (en) * 1997-04-30 2002-12-10 Spectra Logic Corporation Data cartridge library system
US6423688B1 (en) * 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6410746B1 (en) * 1999-04-27 2002-06-25 Research Foundation Of State University Of New York, The Metal cataltsts and methods for making and using same
CA2427271A1 (en) 2000-12-14 2002-06-20 Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
WO2003018183A2 (en) 2001-08-27 2003-03-06 The Research Foundation Of State University Of New York Dirhodium catalyst compositions and methods for using same
US6962891B2 (en) 2001-08-27 2005-11-08 The Research Foundation Of State University Of New York Solid support dirhodium catalyst compositions and methods for making and using same
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US7282519B2 (en) * 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
WO2005077344A2 (en) 2003-08-29 2005-08-25 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
WO2005055810A2 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
ES2439229T3 (es) 2004-10-06 2014-01-22 The Brigham And Women's Hospital, Inc. Relevancia de niveles logrados de marcadores de inflamación sistémica tras el tratamiento
JP2008520578A (ja) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
AU2006206249A1 (en) * 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
CA2597422A1 (en) * 2005-02-16 2007-08-02 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1861093A2 (en) * 2005-03-09 2007-12-05 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1890691A2 (en) 2005-05-31 2008-02-27 Mylan Laboratories, Inc Compositions comrising nebivolol
US7700798B1 (en) 2005-06-08 2010-04-20 The Research Foundation Of State University Of New York Erogorgiaene congeners and methods and intermediates useful in the preparation of same
US7816536B2 (en) * 2005-06-10 2010-10-19 The Research Foundation Of State University Of New York 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
EP1942909A4 (en) * 2005-10-04 2010-01-06 Nitromed Inc METHODS OF TREATING RESPIRATORY DISORDERS
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US7385064B1 (en) 2005-11-30 2008-06-10 The Research Foundation Of State University Of New York Catalysts for use in enantioselective synthesis
EP1971340A2 (en) * 2005-12-22 2008-09-24 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
EP2030025A2 (en) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2081892A4 (en) 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2008131224A2 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7828840B2 (en) * 2007-11-15 2010-11-09 Med Institute, Inc. Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2012511002A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体アンタゴニストとしてのニトロオキシ誘導体
JP5075145B2 (ja) 2009-02-13 2012-11-14 トヨタ自動車株式会社 内燃機関の制御装置
MX2011008952A (es) 2009-02-26 2011-09-27 Merck Sharp & Dohme Activadores de guanilato ciclasa solubles.
US20110190807A1 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2011146371A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
CN103347385A (zh) 2010-10-29 2013-10-09 默沙东公司 二醇二氮烯鎓类杂环衍生物
US8933113B2 (en) 2011-01-20 2015-01-13 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2012148808A1 (en) 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
WO2012151114A1 (en) 2011-05-02 2012-11-08 Merck Sharp & Dohme Corp. Diazeniumdiolate cyclohexyl derivatives
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9108947B2 (en) 2011-10-31 2015-08-18 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
TWI643845B (zh) 2012-05-11 2018-12-11 重植治療公司 隱花色素調節劑之含咔唑磺醯胺類
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CA2881563C (en) 2012-08-01 2021-07-20 Zahra TAVAKOLI Free flowing, frozen compositions comprising a therapeutic agent
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014099836A1 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. Spirocyclic cetp inhibitors
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
EP3079700B1 (en) 2013-12-11 2020-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US9611278B2 (en) 2013-12-11 2017-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US10000484B2 (en) 2013-12-18 2018-06-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassim channel
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
US10590485B2 (en) 2014-05-29 2020-03-17 Geneticure Llc Therapeutic regimen for hypertension
WO2016018729A1 (en) 2014-07-29 2016-02-04 Merck Sharp & Dohme Corp. Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
US9920118B2 (en) 2014-10-31 2018-03-20 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3303342B1 (en) 2015-05-27 2021-03-17 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
US10213429B2 (en) 2015-05-28 2019-02-26 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017011279A1 (en) 2015-07-13 2017-01-19 Merck Sharp & Dohme Corp. Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
WO2017107052A1 (en) 2015-12-22 2017-06-29 Merck Sharp & Dohme Corp. Soluble guanylate cyclase stimulators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
EP3972590A4 (en) 2019-05-22 2023-06-14 Merck Sharp & Dohme LLC NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USED TO TREAT CARDIOMETABOLIC DISEASES, KIDNEY DISEASES AND DIABETES
US20220281886A1 (en) 2019-05-22 2022-09-08 Merck Sharp Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
CN116133660A (zh) 2020-07-22 2023-05-16 詹森药业有限公司 可用作因子XIa抑制剂的化合物
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845079A (en) * 1985-01-23 1989-07-04 Luly Jay R Peptidylaminodiols
ES2066755T3 (es) * 1986-06-10 1995-03-16 Merck Patent Gmbh Derivados de aminoacidos inhibidores de renina.

Also Published As

Publication number Publication date
PH26816A (en) 1992-11-05
NZ229281A (en) 1991-11-26
JPH0267297A (ja) 1990-03-07
NO892136D0 (no) 1989-05-26
EP0343654A3 (en) 1991-05-29
AU3463389A (en) 1989-11-30
AU625456B2 (en) 1992-07-09
NO892136L (no) 1989-11-28
DK258589D0 (da) 1989-05-26
EP0343654A2 (en) 1989-11-29
PT90659B (pt) 1994-10-31
FI892521A0 (fi) 1989-05-24
US5036053A (en) 1991-07-30
FI892521A (fi) 1989-11-28
DK258589A (da) 1989-11-28
KR900018137A (ko) 1990-12-20

Similar Documents

Publication Publication Date Title
PT90659A (pt) Process for the manufacture of diol-containing renin inhibitors
FI882007A (fi) Menetelmä steroidi-5- -reduktaasin inhibiittorien valmistamiseksi
PT87652A (pt) Process for the preparation of peptide bobonic acid inhibitors of trypsin-like proteases
FI883064A (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
FI880941A (fi) Menetelmä terapeuttisesti käyttökelpoisten piperatsinyyli-heterosyklisten yhdisteiden valmistamiseksi
FI96861C (fi) Menetelmä terapeuttisesti aktiivisten substituoitujen indolyylipyrrolijohdannaisten valmistamiseksi
PT86674A (pt) Process for the manufacture of swellable pellets
NO179584C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-acylaminotiazoler
IS1546B (is) Aðferð til framleiðslu afoxandi efnis
IS1667B (is) Hliðstæð aðferð við framleiðslu á meðferðarvirkumbis-aza-bísýklískum efnasamböndum
FI92934B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1-deoksinojirimysiinijohdannaisten valmistamiseksi
FR2640254B1 (fr) Procede de fabrication de trichloromonosilane
FI883997A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten substituoitujen 2-fenyyli-4-kinoliinikarboksyylihappojen valmistamiseksi
FI895393A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten alkyylisubstituoitujen 2-alkyyliamiinibentsopyran-6-olien valmistamiseksi
FI935791A (fi) Menetelmä polyhydroksikarboksyylihapon valmistamiseksi
FI881064A0 (fi) Menetelmä tulehduksenvastaisten tai analgeettisten -aminoetyylisubstituoitujen fenyyliyhdisteiden valmistamiseksi
PT87642A (pt) Process for the preparation of dopamine-beta-hydroxylase inhibitors
FI893003A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI880716A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten aryylipiperatsinyylialkyleenifenyylisubstituoitujen heterosyklisten yhdisteiden valmistamiseksi
NO880851D0 (no) Fremgangsmaate for fremstilling av nye renin-inhibitorer.
NO174200C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser
NO174203C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive
NO177712C (no) Analogifremgangsmåte for fremstilling av nye terapeutisk virksomme alkylfosfonoseriner
PT88545A (pt) Process for the manufacture of benzimidazoline-2-oxo-1-carboxylic acid derivative compounds
FI91069B (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19940407

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19951031